A look at the following clinical trial: Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer (SN-FNAC)
TY - JOUR. T1 - Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer. T2 - A meta-analytical evaluation of prospective studies. AU - Festa, Virginia. AU - Andriulli, Angelo. AU - Valvano, Maria Rosaria. AU - Uomo, Generoso. AU - Perri, Francesco. AU - Andriulli, Nicola. AU - Corrao, Salvatore. AU - Koch, Maurizio. PY - 2013. Y1 - 2013. N2 - Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies where chemotherapy with or without radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a metaanalytical approach. Main outcome measures Primary outcome was surgical exploration and resection rates; tumor response, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence intervals ...
TY - JOUR. T1 - [Curative laparoscopic surgery performed after neoadjuvant chemotherapy for locally advanced rectal cancer invading into the vagina].. AU - Ohtsuka, Masahisa. AU - Mizushima, Tsunekazu. AU - Ohta, Katsuya. AU - Nishimura, Junichi. AU - Takemasa, Ichiro. AU - Ikeda, Masataka. AU - Yamamoto, Hirofumi. AU - Sekimoto, Mitsugu. AU - Doki, Yuichiro. AU - Mori, Masaki. PY - 2011/1/1. Y1 - 2011/1/1. N2 - A 60-year-old woman with locally advanced rectal cancer, which had infiltrated into the vagina, was referred to our department in September 2010. She received 4 courses of neoadjuvant chemotherapy; the tumor size reduced, but the fistula was not closed. Because the tumor size had reduced, we performed a laparoscopic surgery. The laparoscopic surgery involved perineal proctectomy and resection of the posterior wall of the vagina, along with dissection of the bilateral lymph nodes. The efficacy of the neoadjuvant chemotherapy was judged as Grade 2. Neoadjuvant chemotherapy should be ...
Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively. These findings were presented by Sun et al at the Annual Meeting of the American Society of Breast Surgeons (ASBrS). The new study compared the clinicopathologic characteristics of patients with HER2-positive breast cancer who had no evidence of residual cancer on a pathology report following neoadjuvant chemotherapy with those who did.. "More than 56,000 cases of HER2-positive breast cancer, a comparatively aggressive tumor, are diagnosed in the United States annually," said lead researcher Susie Sun, MD, of The University of Texas MD Anderson Cancer Center. "Evidence is growing that certain patients are exceptional neoadjuvant chemotherapy responders, suggesting that when properly identified, someday certain … ...
PRIMARY OBJECTIVES:. I. To estimate the median overall survival of patients with adenocarcinoma of the pancreas treated with induction chemotherapy, neoadjuvant chemoradiotherapy, surgical resection and adjuvant chemotherapy.. SECONDARY OBJECTIVES:. I. To determine the percent of patients surviving at annual intervals through five years.. II. To determine the median recurrence free survival following pancreaticoduodenectomy.. III. To determine the clinical response rate to neoadjuvant chemotherapy and chemoradiotherapy.. IV. To determine the pathologic response rate to neoadjuvant chemotherapy and chemoradiotherapy.. V. To determine the cancer antigen (CA) 19-9 tumor marker response rate to neoadjuvant chemotherapy and chemoradiotherapy.. VI. To determine the surgical completion rate and complication rate following neoadjuvant chemotherapy and chemoradiotherapy.. VII. To determine the frequency and severity of toxicities associated with this treatment regimen.. OUTLINE:. INDUCTION CHEMOTHERAPY: ...
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy.. A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients. The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy.. Their meta-analysis suggest that patients ...
TY - JOUR. T1 - Doxorubicin-based neoadjuvant chemotherapy is associated with Poorer Five-Year Survival in patients with locally advanced breast cancer. T2 - A retrospective single-center study in Indonesia. AU - Oktaviani, Nuraini. AU - Sutrisna, Bambang. AU - Panigoro, Sonar Soni. AU - Mulia, Dina Dwi. AU - Megawati, AU - Yulian, Erwin. PY - 2019/1/1. Y1 - 2019/1/1. N2 - One of the therapeutic modalities used to improve survival rate in breast cancer is neoadjuvant chemotherapy, which generally follows a doxorubicin-based regimen for patients with locally advanced breast cancer treated at Cipto Mangunkusumo General Hospital (CMGR). Five-year survival rates with doxorubicin-based versus non-doxorubicin-based neoadjuvant chemotherapy in locally advanced breast cancer are not known. To determine five-year overall survival (OS) in patients with locally advanced breast cancer who underwent doxorubicin or non-doxorubicin-based neoadjuvant chemotherapy at CMGR between 2011 and 2016. Clinical data of ...
Another rationale for neoadjuvant systemic therapy is that this allows for the immediate treatment of micrometastases; however, this has not been associated with an increase in survival in most trials to date (Figs. 85-1B and 85-1C). In contrast, a major advantage is that tumor response to chemotherapy is a strong predictor of outcome. Thus neoadjuvant systemic therapy can be used as an in vivo assay of systemic therapy efficacy. This, in theory, can allow for testing of new therapy regimens in the neoadjuvant setting, allowing for shorter and smaller trials to be conducted using chemotherapy response as the primary end point. In addition, the neoadjuvant setting allows the opportunity to identify biomarkers that can predict response as well as identify pharmacodynamic markers of response, that is to say, markers that can change within the primary tumor with the administration of chemotherapy, which can be an early molecular signal of therapy activity. Although the standard of care at this point ...
This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and SBRT in borderline resectable pancreatic cancer.
PRIMARY OBJECTIVES:. To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT) after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.. SECONDARY OBJECTIVES:. I. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly prolong overall survival (OS) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.. II. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly ...
ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide
View Poster. INTRODUCTION. Pathological response following neoadjuvant chemotherapy (NAC) has been shown to be an excellent surrogate for survival in bladder cancer. In upper tract urothelial cancer (UTUC), unlike bladder, preoperative endoscopic and pathologic assessment of response is difficult. The aim of this study is to determine whether imaging response following NAC predicted the final pathologic stage and outcomes following radical nephroureterectomy (NU).. METHODS. We identified all radical nephroureterectomies performed at our institution from January 1995 until July 2017. All cytology and biopsy proven, ≥cT2anyNM0 high grade UTUC patients who underwent NAC with cisplatinum based chemotherapy prior to RNU were analyzed. Evaluation with CT/MR urography was available both before and after NAC. Radiological response rate (RRR) was estimated using the RECIST criteria and pathologic response was defined as RESULTS. Of the 685 NUs performed during the study period, 62 (9.1%; 95% CI 7.1%, ...
Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified neoadjuvant radiochemotherapy on long term cancer related and disease free survival. A total of 387 patients underwent oncologic resection for rectal cancer in our institution between January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy protocol completely and without excluding criteria (study group). A matched pair analysis was performed by comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status, tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according
BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD). METHODS: The study population was comprised of 240 consecutive patients with PDAC who received neoadjuvant chemoradiation and PD and was compared with 60 patients who had no neoadjuvant therapy between 1999 and 2007. Clinicopathologic features were correlated with disease-free survival (DFS) and overall survival (OS). RESULTS: Among the 240 treated patients, the 1-year and 3- year DFS rates were 52% and 32%, with a median DFS of 15.1 months. The 1-year and 3-year OS rates were 95% and 47%, with a median OS of 33.5 months. By univariate analysis, DFS was associated with age, post-therapy tumor stage (ypT), lymph node status (ypN), number of positive lymph nodes, and American Joint Committee on Cancer (AJCC) stage, ...
Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments for patients with early breast cancer and for the highly productive translational research which they facilitate. Meta-analysis of trial data shows clear correlation between pathological response at surgery after neoadjuvant chemotherapy and longer-term outcomes at an individual patient level. However, this does not appear to be present on individual trial level analysis, when correlating improved outcome for the investigational arm for the primary endpoint (pathological response) with longer-term outcomes. The correlation between pathological response and longer-term outcomes in trials is dependent on many factors. These include definitions of pathological response, both complete and partial; assessment methods for pathological response at surgery; subtype and prognosis of breast cancer at diagnosis; number of patients recruited; adjuvant treatments; the mechanism of action of the investigational drug; the
OBJECTIVES. Primary. To determine the change from baseline to post-treatment Ki67 values in ER-positive, HER2-negative ILC tissue derived from postmenopausal women awaiting definitive surgery or further neoadjuvant treatment who are randomized to 21-24 days of neoadjuvant endocrine treatments with fulvestrant (two 250 mg IM injections given on day 1), anastrozole (1mg given orally daily), or tamoxifen (20mg given orally daily).. Secondary. - To evaluate ER protein expression in ILC tissues at baseline and following neoadjuvant endocrine therapy.. - To evaluate PR protein expression in ILC tissues at baseline and following neo-adjuvant endocrine therapy.. - To evaluate ER-related and ILC-specific candidate gene mRNA expression in ILC tissues at baseline and following neoadjuvant endocrine therapy in an effort to identify biomarkers of endocrine response and putative drivers of endocrine resistance in ILC.. - To evaluate associations between changes in Ki67 in ILC tissues following neoadjuvant ...
BACKGROUND We systematically reviewed and performed a meta-analysis of the available data regarding neoadjuvant chemo- and/or radiotherapy with special emphasis on tumor response/progression rates, toxicities, and clinical benefit, i.e. resection probabilities and survival estimates. METHODS AND FINDINGS Trials were identified by searching PUBMED, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1966 to Feb 2015. A total of 18 studies (n = 959) were analyzed. the estimated fraction of patients with complete response was 2.8% (CI 0.8-4.7%) and with partial response 28.7% (CI 18.9%-38.5%). Stable disease was averaged to 45.9% (CI 32.9%-58.9%) in all patients and tumor progression under therapy occurred by estimation in 16.9% (CI 10.2%-23.6%) of the patients. The weighted frequency of those who underwent resection was 65.3% (CI 54.2%-76.5%), and the proportion of R0 resection amounted to 57.4% (CI 48.2%-66.5%). The weighted mean of median survival amounted to 17.9 months (range: 14.7
of response to neoadjuvant therapy in stage IIIA NSCLC patients in relation to T factor and N factor; evaluation of TNM classification before and after use of neoadjuvant therapy in stage IIIA NSCLC patients; determination of degree of tumor regression with pathohistologic analysis of resection specimen of NSCLC obtained from patients after application of neoadjuvant therapy, as a prognostic factor for disease-free period and overall survival rate; and determination of degree of tumor regression in malignant lymph nodes after application of neoadjuvant therapy in stage IIIA NSCLC patients, as a prognostic factor for disease-free period and overall survival rate. Results have shown that neoadjuvant therapy according to RECIST criteria leads to significant reduction of tumor size, T factors, as well as significant downstaging of nodal status, N factor, in treatment of stage IIIA NSCLC patients. Furthermore, neoadjuvant therapy according to RECIST criteria leads to significant reduction of clinical ...
Many data suggest that patients with low rectal adenocarcinoma who achieved ypT0N0 status have improved survival and disease-free survival (DFS) compared to all other stages however only few data are available regarding the specific prognosis factors of this subgroup. This study aimed to evaluate predictive factors for disease free survival after complete pathological response (CPR) in cases of low rectal adenocarcinoma. From January 2005 to December 2013, all patients with low rectal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by total mesorectal excision and achieved CPR were included at 7 Moroccan and 1 Algerian centres. Predictive factors for disease-free survival were analysed by uni and multivariate analysis. Eigthy-four (12.1%) patients achieved a CPR (ypT0N0). Multivariate analysis revealed that both poorly differentiated tumors (OR, 9.23; 95 CI 1.35-62.82; P = 0.023) and the occurrence of perineal sepsis (OR, 13.51; 95 CI 1.96-93.12; P = 0.008) were independently
TY - JOUR. T1 - Color-Doppler using contrast medium in evaluating the response to neoadjuvant treatment in patients with locally advanced breast carcinoma. AU - Vallone, Paolo. AU - D'Angelo, Roberto. AU - Filice, Salvatore. AU - Petrosino, Teresa. AU - Rinaldo, Massimo. AU - De Chiara, Anna. AU - Gallipoli, Adolfo. PY - 2005/1. Y1 - 2005/1. N2 - Background: The aim of our study was to assess the color-Doppler ultrasound (CDU) pattern in the analysis of neoadjuvant preoperative treatment of patients with locally advanced breast carcinoma, improvement after injection of contrast medium (Levovist) and possible correlations between morphological and vascular aspects of the neoplasm and postoperative histopathological findings. Materials and Methods: We studied 50 patients affected by locally advanced breast carcinoma (T3a e b-T4), using CDU before and after injection of Levovist, prior to and after neoadjuvant chemotherapeutic treatment. Results: The use of Levovist for ultrasound examinations ...
Management of oesophageal cancer is associated with poor outcomes and it has become apparent that surgery alone is not sufficient to effect genuine long term survival. In the UK, it is standard practice to treat oesophageal adenocarcinoma with neo-adjuvant chemotherapy (no radiation) and surgery. One problem with this approach is the issue of those patients who do not respond. The aim of this study was to investigate biomarkers which might predict response to chemotherapy. Methods A retrospective audit was carried out on post-operative outcome after oesophagectomy from 2000 to 2006 and results compared with those from previous similar audits. Patients who received neo-adjuvant chemotherapy were identified and pre-treatment oesophageal biopsies were obtained. Immunohistochemistry was used to analyse expression ofthymidylate synthase, excision cross-complementation group 1, vascular endothelial growth factor, hypoxia-inducible factor 1 and carbonic anhydrase IX. Expression was compared with ...
This phase II study demonstrates the feasibility of preoperative chemoradiation with bevacizumab and capecitabine in patients with LARC. Indeed, a high R0 resection rate was achieved despite tumour invasion of the mesorectal fascia in 46% of patients. A well-accepted approach in the management of LARC is neoadjuvant fluoropyrimidine-based chemoradiation and a number of prospective and retrospective trials have suggested that preoperative capecitabine is at least equivalent to infusional 5-fluorouracil when combined with RT [16-19], and may improve tumour downstaging. In 2009, the US National Comprehensive Cancer Network recommended capecitabine as an acceptable alternative to 5-FU in this setting [36].. The pCR rate of 13% observed with neoadjuvant capecitabine plus bevacizumab plus RT was similar to an earlier phase II study by our group examining neoadjuvant single-agent capecitabine plus RT in LARC [37]. This pCR rate, albeit relatively low, is within the range 0-31% reported across a number ...
Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%. The standard of care for locally advanced disease is neoadjuvant chemotherapy or, more commonly, combined neoadjuvant chemoradiation therapy (neo-CRT) prior to surgery. Unfortunately, ~60-70% of patients will fail to respond to neo-CRT. Therefore, the identification of biomarkers indicative of patient response to treatment has significant clinical implications in the stratification of patient treatment. Furthermore, understanding the molecular mechanisms underpinning tumour response and resistance to neo-CRT will contribute towards the identification of novel therapeutic targets for enhancing OAC sensitivity to CRT. MicroRNAs (miRNA/miR) function to regulate gene and protein expression and play a causal role in cancer development and progression. MiRNAs have also been identified as modulators of key cellular ...
Neoadjuvant chemotherapy has already been wildly accepted as a comprehensive therapeutic strategy, especially for local advanced lung cancer [12]. When most patients obtain accurate diagnosis, surgery may have not been as the first choice [3]. However, NSCLC cells developed resistance to chemotherapy. That is one of the main reasons that the patients get poor outcomes (5-year over survival , 10%) [13-15]. Furthermore, neoadjuvant chemotherapy was usually in experimental phases, and only a few patients get ideal effects [5]. For most patients with lymph node metastasis or with incompletely resection, chemotherapy is useless but increases the burden of patients.. An increasing number of researches indicate that there were lots of chemopredictive biomarkers such as DNA repair genes like ERCC1, β-tubulins or topoisomerases [16-18]. Ku80 as a key mediator of DNA DSB repair has been reported that its expression level could predict the prognosis and sensitivity to cisplatin [1, 19]. To determine this ...
Neoadjuvant chemoradiotherapy does not offer greater survival for stage IIIA/N2 non-small-cell lung cancer patients than neoadjuvant chemotherapy
Introduction A reduction in the Ki-67 index after neoadjuvant chemotherapy has been reported to be associated with a favorable prognosis. The present study investigates whether a reduction in Ki-67 may be a predictive surrogate marker of favorable prognosis in each subtype of breast cancer.. Methods A total of 385 patients who received neoadjuvant anthracycline followed by taxane chemotherapy and subsequent surgery for invasive breast cancer were analyzed retrospectively. By immunohistochemistry (IHC), patients were divided into 4 subtypes (Luminal A, Luminal B, Triple negative and HER2). Ki-67 was examined by IHC in pre-treatment core needle samples and post-treatment surgical excisional specimens. The relapse-free survival (RFS) rate was compared among each subtype.. Results The median follow-up period was 56 months. The rate of pathological complete response was higher for HER2 (34.8%) and Triple negative (24.3%) subtypes than for Luminal B (8.3%) and Luminal A (3.8%) subtypes (p < 0.0001). A ...
MIAMI-As neoadjuvant therapy for breast cancer, docetaxel (Taxotere) plus cisplatin delivers pathologic complete response rates as good or better than standard anthracycline-containing regimens, results of a nonrandomized study suggest. The study involved 57 patients with locally advanced and inflammatory breast cancer. 1
Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response. A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting. An international working group was convened to develop practical recommendations for the pathologic assessment of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with radiological findings is ...
Abstract: Objective: To evaluate the clinical relevance of preoperative airway colonisation in patients undergoing oesophagectomy for cancer after a neoadjuvant chemoradiotherapy. Methods: From 1998 to 2005, 117 patients received neoadjuvant chemoradiotherapy for advanced stage oesophageal cancer. Among them, 45 non-randomised patients underwent a bronchoscopic bronchoalveolar lavage (BAL group) prior to surgery to assess airways colonisation. The remaining patients (n =72) constituted the control group. The two groups were similar with respect to various clinical or pathological characteristics. Results: Thirteen of the 45 BAL patients (28%) had a preoperative bronchial colonisation by either potentially pathogenic micro-organisms (PPMs) (n =7, 16%) or non-potentially pathogenic micro-organisms (n =6, 13%). Cytomegalovirus (CMV) was cultured from BAL in four patients. Pre-emptive therapy was administrated in seven patients: four antiviral and three antibiotic prophylaxes. Postoperatively, 14 ...
Purpose: Preoperative chemoradiotherapy followed by surgery represents the standard of care for locally advanced rectal cancer (LARC). Cetuximab has proved activity in advanced colorectal cancer, and its incorporation in preoperative treatment may increase tumor downstaging. Methods and Materials: After biopsy and staging, uT3/uT4 N0/+ LARC received single-agent cetuximab in three doses, followed by weekly cetuximab plus 5-fluorouracil (5-FU), concomitantly with RT. Sample size was calculated according to Bryant and Day test, a two-stage design with at least 10 pathologic complete remissions observed in 60 patients (pts) able to complete the treatment plan. Results: Forty pts with LARC were entered: male/female = 34/6; median age: 61 (range, 28-77); 12 uT3N0 Ed(30%); 25 uT3N1 (62%); 3 uT4N1 (8%); all Eastern Cooperative Oncology Group = 0. Thirty-five pts completed neoadjuvant treatment; 5 (12%) withdrew therapy after one cetuximab administration: three for hypersensitivity reactions, one for ...
Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.
A retrospective cohort study assessed Residual Cancer Burden (RCB), a standardized measure of residual disease in pathologic resection specimens following neoadjuvant chemotherapy, which was found to be prognostic of long-term survival in which breast cancer phenotypes? ...
Treatment given to weaken and destroy breast cancer BEFORE surgery is called neoadjuvant treatment. Neoadjuvant treatment isnt used routinely to treat early-stage breast cancer, but may be used if the cancer is large or aggressive. Neoadjuvant treatment is more likely to be used before surgery to treat breast cancer that has spread outside the breast to other tissue in the breast area (locally advanced breast cancer). One or more chemotherapy medicines are usually used for neoadjuvant treatment.. A study found that adding the targeted therapy Avastin (chemical name: bevacizumab) to a neoadjuvant chemotherapy combination didnt benefit women diagnosed with early-stage or locally advanced breast cancer. The results were presented at the 2010 San Antonio Breast Cancer Symposium (SABCS).. Avastin is a targeted therapy medicine that is given intravenously. Avastin works by blocking the growth of new blood vessels that cancer cells need to grow and function. A protein called vascular endothelial ...
For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft tissue sarcoma (STS). Soft tissue […]. ...
About PACIFIC. The PACIFIC trial is a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi as sequential treatment in unselected patients with locally-advanced, unresectable (Stage III) NSCLC who have not progressed following platinum-based chemotherapy concurrent with radiation therapy.. The trial is being conducted in 235 centres across 26 countries and regions, including the US, Canada, Europe, South and Central America, Japan, Korea, Taiwan, South Africa and Australia. The primary endpoints of the trial are PFS and OS, and secondary endpoints include landmark PFS and OS, objective response rate and duration of response.. About Imfinzi. Imfinzi (durvalumab), a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumours immune-evading tactics and inducing an immune response.. Imfinzi continues to be studied in multiple monotherapy trials and combination trials with tremelimumab and other potential new ...
Learn about how PERJETA-based neoadjuvant therapy is used for HER2+ early breast cancer. See Full Safety including Boxed Warnings for more information.
Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for oesophageal malignancy
BACKGROUND: Rectum-sparing approaches appear to be appropriate in rectal cancer patients with a major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The aim of the present study is to evaluate the effectiveness of rectum-sparing approaches at 2 years after the completion of neoadjuvant treatment. STUDY DESIGN: Patients with rectal adenocarcinoma eligible to receive neoadjuvant therapy will be prospectively enrolled. Patients will be restaged 7-8 weeks after the completion of neoadjuvant therapy and those with mCR (defined as absence of mass, small mucosal irregularity no more than 2 cm in diameter at endoscopy and no metastatic nodes at MRI) or cCR will be enrolled in the trial ...
Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium.
The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with locally-advanced clear
Introduction: Based on high-throughput transcriptional profiling and array comparative genomic hybridization, a three-gene predictor encompassing c-MYC, EGFR and FGFR2 has been identified to predict survival in cisplatin and fluorouracil (FU) - treated metastatic gastric cancer (GC) patients by others (1).. The aim of our study was to determine the value of the expression of these three genes to predict response and/or survival for GC patients treated by a platin/5FU based chemotherapy in the neoadjuvant setting.. Material and methods: Expression was analyzed in pretherapeutic tumor biopsies of 69 patients treated by platinum/5FU based neoadjuvant chemotherapy. Histopathological response was divided into three grades, tumor regression grade 1 (TRG1) corresponding to complete/major response, TRG2 corresponding to partial and TRG3 corresponding to minimal or no response. mRNA was isolated from manually microdissected formalin fixed and paraffin embedded tumor biopsies. Relative quantification of ...
SPARE is a multicentre randomised controlled trial comparing RC and SBP in patients with MIBC staged T2-3 N0 M0, fit for both treatment strategies and receiving three cycles of neoadjuvant chemotherapy. Patients were randomised between RC and SBP before a cystoscopy after cycle three of neoadjuvant chemotherapy. Patients with ≤T1 residual tumour received a fourth cycle of neoadjuvant chemotherapy in both groups, followed by radical RT in the SBP group and RC in in the RC group; non-responders in both groups proceeded immediately to RC following cycle three. Feasibility study primary endpoints were accrual rate and compliance with assigned treatment strategy. The phase III trial was designed to demonstrate non-inferiority of SBP in terms of overall survival (OS) in patients whose tumours responded to neoadjuvant chemotherapy. Secondary endpoints included patient-reported quality of life, clinician assessed toxicity, loco-regional recurrence-free survival, and rate of salvage RC after ...
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) f
This trial evaluated the effect of paclitaxel, doxorubicin, and cyclophosphamide, methotrexate and fluorouracil (CMF) neoadjuvant chemotherapy, with and without
Research Zhipeng Sun and Nengwei Zhang World Journal of Surgical Oncology 2014, 12:397 doi:10.1186/1477-7819-12-397 Published: 29 December 2014 Abstract (provisional) Background In the ... Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?
The poor prognosis of gastric carcinoma has remained unchanged for the past 2 decades with a 5-year-survival rate ranging between 40% and 50%. Surgery is the only curative treatment option for locally advanced disease. Furthermore, most patients are initially diagnosed at advanced tumor stages. Despite curative resection (R0), the overall recurrence rate is 69%. Locoregional relapse (87%) as well as lymphatic and peritoneal metastasis have a high likelihood [1, 4, 6]. Radiation and chemotherapy aim at controlling local tumor spread and eliminating disseminated tumor cells to prolong survival [18]. Intraoperative radiation succeeded in reducing locoregional relapse, but failed in improving overall survival [5]. The palliative implementation of PELF-CTx had a significant impact on the median survival [19]. Therefore, we investigated the influence of this protocol in the neoadjuvant setting on morbidity and mortality, tumor recurrence and prognosis.. Regarding size, our study ranges in the lower ...
Rectal cancer Improvements in management of rectal cancer in past decades Preoperative accurate tumor staging Good surgical technique (TME) Neoadjuvant / adjuvant therapy Improved pathological assessment identifying adequacy of resection
The purpose of this study is to evaluate the efficacy and safety of docetaxel plus cyclophosphamide(TC) compared with docetaxel, anthracycline, and cyclophosphamide(TEC) in neoadjuvant treatment of triple negative or HER2 positive breast cancer. Elig
Purpose To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer.. Patients and Methods Patients with operable magnetic resonance imaging-defined high-risk rectal cancer received four cycles of capecitabine/oxaliplatin (CAPOX) followed by capecitabine chemoradiotherapy, surgery, and adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab (CAPOX + C). The primary end point was complete response (CR; pathologic CR or, in patients not undergoing surgery, radiologic CR) in patients with KRAS/BRAF wild-type tumors. Secondary end points were radiologic response (RR), progression-free survival (PFS), overall survival (OS), and safety in the wild-type and overall populations and a molecular biomarker analysis.. Results One hundred sixty-five eligible patients were randomly assigned. Ninety (60%) of 149 assessable tumors were KRAS or BRAF wild type (CAPOX, n = 44; CAPOX + C, n = 46), and in these patients, the addition of ...